drugset / Trial / NCT00367484
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objectives of the study are: \- comparison of the incidence and time course of the development of neutralizing antibodies (NAbs) to Rebif after 48 weeks of therapy, to historical data from Serono clinical trial databases to assess the safety and tolerability of Rebif®
Timeline
- Start
- 2004-05
- Primary completion
- 2006-01
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant-human interferon beta-1a | Protein / enzyme biologic | 44 ug | Subcutaneous |